Latest news for Chugai Pharmaceutical (OTC:CHGCF) Stock

Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra for hemophilia A patients and tocilizumab for treating rheumatoid arthritis and covid-19 patients.

News

Penny Stocks

Health Care

Small Cap

Markets

Analyst Ratings

Trading Ideas

General

ABBV

ABOS

ALXO

ANVS

ARGNF

CHGCF

HALO

RHHBY

Halozyme Therapeutics (NASDAQ: HALO) announced that it has been granted a new patent in the EU that covers the ENHANZE rHuPH20 product, which is produced using the company&#39;s proprietary ENHANZE manufacturing methods.

Halozyme&#39;s ENHANZE Product Gets New Patent Grant in EU

CHUGAI PHARMACEUTICAL by Chugai Pharmaceutical Co., Ltd.

Chugai Pharmaceutical Co Ltd

Chugai Pharmaceutical Co., Ltd. (CHGCF) Q1 2024 Earnings Call Transcript

Chugai Pharmaceutical Co (JP:4519) has released an update. Chugai Pharmaceutical Co. reports that its performance for the first half of 2024 has be...

Chugai Pharmaceutical Included in Roche's 2024 Results

Chugai Pharmaceutical Co (JP:4519) has released an update. Chugai Pharmaceutical Co., Ltd. reports a solid performance in the first half of FY 2024...

Chugai Pharmaceutical's H1 Profits and Dividends Up

Chugai Pharmaceutical reports 1H results

Chugai Pharmaceutical Co (JP:4519) has released an update. Chugai Pharmaceutical Co., Ltd. has announced corrections to its previously disclosed 20...

Chugai Pharmaceutical Corrects Financial Statements

Chugai Pharmaceutical Co., Ltd. (CHGCF) Q2 2024 Earnings Call Transcript

Invesco Developing Markets Fund Q2 2024 Quarterly Review

Harding Loevner International Equity Q2 2024 Report

Harding Loevner International Equity ADR Q2 2024 Report

Harding Loevner International Developed Markets Equity Q2 2024 Report

AAUKF

ADYEY

ADYYF

ASAZF

ASAZY

ASML

ASMLF

BBVA

BBVXF

BHPLF

BNDSF

BNDSY

BSAC

CHGCY

DBSDF

DBSDY

FMXUF

GBOOF

GBOOY

GLPEF

GLPEY

GMAB

GMBXF

GNMSF

HTHT

IFNNF

IFNNY

INFY

LZRFY

MDTTF

MPLX

MPLXP

NGLOY

NHNCF

NONOF

NSRGF

NSRGY

NVDA

PAAPU

PDRDF

PRNDY

SAPGF

SBGSF

SBGSY

SGIOF

SGIOY

SNEJF

SONY

SSNLF

TCEHY

TCTZF

TSMWF

USAC

WMMVF

WMMVY

YUMC

ZTOEF

Chugai Pharmaceutical

Halozyme Therapeutics&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) announced that it has been granted a new patent in the EU that covers the ENHANZE rHuPH20 product, which is produced using the company&#39;s proprietary ENHANZE manufacturing methods.

Per the press release, the new patent is included in all of Halozyme&#39;s existing and future ENHANZE licenses, meaning that all of its licensees will benefit from this patent. The patent is set to be validated in 37 EU countries, where it will be legally recognized and enforceable, until the expiry date of Mar 6, 2029.

The new patent grant is a significant intellectual property milestone for HALO, ensuring protection and control over its ENHANZE rHuPH20 product across a wide geographical area in the EU until 2029. This enhances the company&#39;s competitive edge and provides security for its product and associated technologies.

Shares of the company gained 2.3% in the after-market hours on Jun 5 in response to the encouraging news. Year to date, the stock has jumped 23.5% against the industry&#39;s 5.6% decline.

<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/9c/68295.jpg?v=246700835" style="height:350px; width:600px" /> 
Image Source: Zacks Investment Research

ENHANZE is Halozyme&#39;s novel drug delivery technology that facilitates the subcutaneous administration of drugs. The company currently licenses this technology to leading pharmaceutical companies, including Roche (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>), Takeda (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAK#NYSE">TAK</a>), Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), J&amp;J (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), Argenx (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ARGNF#OTC">ARGNF</a>), ViiV Healthcare, Chugai Pharmaceutical&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/CHGCF#OTC">CHGCF</a>) and Acumen Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABOS#NASDAQ">ABOS</a>).

These companies are using this technology for developing SC formulations of their currently marketed drugs. Halozyme earns royalties on sales of seven commercial products by its partners including from J&amp;J for subcutaneous formulation of its multiple myeloma drug, Darzalex (daratumumab).

Based on this new patent grant, management believes that it will be able to maintain the original royalty rate for J&amp;J&#39;s Darzalex SC, in the EU through March 2029.

Per the terms of the licensing agreement with JNJ, the new EU patent prevents a reduction in the royalty rate paid by J&amp;J for sales of Darzalex SC to Halozyme in the EU countries where it is validated. This implies that until the patent expires in 2029, HALO will continue to receive the same royalty rate from J&amp;J, providing financial stability and sustained revenues from this partnership.

For other ENHANZE licenses, Halozyme does not expect the new patent to impact the existing royalty arrangements. These licenses already have issued or pending collaboration patents that ensure the current royalty rates will extend beyond the expiration date of the new patent.

Therefore, revenues from these other licenses are already secured and unaffected by the latest patent, maintaining HALO&#39;s overall financial expectations and stability from its ENHANZE licensing agreements.

In the first quarter of 2024, the company recorded $120.6 million in royalties, representing an increase of 21% year over year, primarily driven by robust demand for JNJ&#39;s Darzalex and Roche&#39;s Phesgo. For the full year, Halozyme anticipates its royalty revenues in the range of $500-$525 million.

<div class="chart_embed">
<h3>Halozyme Therapeutics, Inc. Price and Consensus</h3>
<a href="https://www.zacks.com/stock/chart/HALO/price-consensus-chart?icid=chart-HALO-price-consensus-chart"><img alt="Halozyme Therapeutics, Inc. Price and Consensus" src="https://staticx-tuner.zacks.com/images/charts/be/1717668155.png" style="height:350px; width:500px" title="" /> </a>

Halozyme Therapeutics, Inc. price-consensus-chart &#x7C; Halozyme Therapeutics, Inc. Quote
</div>

<h3>Zacks Rank and Stocks to Consider</h3>

Halozyme currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from the drug/biotech industry are ALX Oncology Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALXO#NASDAQ">ALXO</a>) and Annovis Bio (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANVS#NYSE">ANVS</a>), each carrying a Zacks Rank #2 (Buy) at present.

In the past 30 days, the Zacks Consensus Estimate for ALX Oncology&#39;s 2024 loss per share has narrowed from $3.33 to $2.89. During the same period, the consensus estimate for 2025 loss per share has narrowed from $2.85 to $2.73. Year to date, shares of ALXO have plunged 40.9%.

ALX Oncology beat estimates in two of the trailing four quarters and missed twice, delivering an average negative surprise of 8.83%.

In the past 30 days, the Zacks Consensus Estimate for Annovis&#39; 2024 loss per share has narrowed from $2.93 to $2.46. During the same period, the consensus estimate for 2025 loss per share has narrowed from $2.83 to $1.95. Year to date, shares of ANVS have plunged 64%.

ANVS beat estimates in three of the trailing four quarters and missed once, delivering an average negative surprise of 1.39%.

<a href="https://www.zacks.com/stock/news/2284729/halozyme-s-halo-enhanze-product-gets-new-patent-grant-in-eu?cid=CS-BENZ-FT-analyst_blog&#x7C;company_news_medical_sector-2284729">To read this article on Zacks.com click here.</a>

Halozyme's ENHANZE Product Gets New Patent Grant in EU

Today&#39;s 5 Stock Ideas:&nbsp;

<ul>
	<li>Alibaba (BABA)&nbsp;- Shares were lower Friday morning, likely on the heels of a WSJ&nbsp;<a href="https://www.wsj.com/articles/china-plans-to-ban-u-s-ipos-for-data-heavy-tech-firms-11630045061?mod=hp_lead_pos2">article</a>&nbsp;&quot;China Plans to Ban U.S. IPOs for Data-Heavy Tech Firms.&quot;</li>
	<li>Zoom Video Communications (ZM)&nbsp;- Will report Q2 earnings on Monday after the close of the stock market.</li>
	<li>Cassava Sciences (SAVA)&nbsp;- One of Friday morning&#39;s most-discussed stocks. Shares were down about 20% following a release by&nbsp;Quanterix (QTRX)&nbsp;that commented on Cassava&#39;s recent data for its Alzheimer&#39;s candidate. The Benzinga newsdesk did not detect any negative sentiment shared by Quanterix that might justify the move lower in Cassava, but the Quanterix press release did seem to be the catalyst Friday morning.</li>
	<li>Support.com (SPRT)&nbsp;- The stock remains the most-searched ticker on Benzinga Pro over the last 24 hours. Shares were up more than 100% Friday morning amid high short interest and a low float for the stock. The Benzinga newsdesk did not see fundamental news to justify the move sharply higher.</li>
	<li>Chegg (CHGG)&nbsp;- Company CFO, Andrew Brown, will interview on Benzinga&#39;s &quot;Power Hour&quot;&nbsp;<a href="https://www.youtube.com/channel/UCqQs28K2zj2dOsc5NfXUKEg">YouTube</a>&nbsp;show Friday at 12:30 p.m. EDT.</li>
</ul>

Pre-Market Outlook

BABA

QTRX

SAVA

SPRT

Benzinga Pro's Top 5 Stocks To Watch For Friday, Aug. 27, 2021: BABA, ZM, SAVA, SPRT, CHGG

On August 16, 2014 (Japan time), there was a media report regarding Roche's (OTC: <a class="ticker" href="/stock/rhhby#OTC">RHHBY</a>) intention to own 100% of Chugai (OTC: <a class="ticker" href="/stock/chgcf#OTC">CHGCF</a>) shares. This report is not based on any announcement made by Chugai or Roche.
 
Chugai is in no way in the process of reviewing any plan to become a wholly-owned subsidiary of Roche, nor discussing with Roche about such a transaction.
 
Roche, as usual, is not commenting on any market rumors.

Rumors

Global

Chugai Pharmaceutical Denies it is in Talks to be Acquired by Roche

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Chugai Pharmaceutical

News

Latest news for Chugai Pharmaceutical (OTC:CHGCF) Stock

Thursday, June 06, 2024

Friday, August 27, 2021

Sunday, August 17, 2014